Manifold Bio: Unlocking tissue-specific delivery via high throughput in vivo discovery

Manifold Bio thinks the way to finally crack tissue-specific delivery of biologics is to conduct discovery work in vivo. Six years in, the Boston-based biotech has built a massively parallel in vivo screening platform and attracted Roche as a partner to develop next-generation blood-brain barrier shuttles.

Roche (SIX:ROG; OTCQB:RHHBY) itself has long been a leader in BBB shuttle development. Phase II data from the pharma’s shuttle-enabled Alzheimer’s therapy trontinemab has helped validate the iron transporter, TfR, an effective portal for delivering antibody therapies deeper into the brain at lower systemic doses...